Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re FDA Decision: Celldex Therapeutics (CLDX)

The Phase 2 date for Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re by Celldex Therapeutics (CLDX) is scheduled for March 15, 2027. This is the target date for the FDA to make a decision on this application.

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re is being developed by Celldex Therapeutics for the treatment of its target indication. It is currently in Phase 2 clinical trials.

If Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re receives FDA approval, Celldex Therapeutics (CLDX) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 2 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for CLDX on DilutionWatch at dilutionwatch.com/stock/CLDX.html.

You can view the full BiotechSign company profile for Celldex Therapeutics (CLDX) at biotechsign.com/app/company/CLDX, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.